{"id":"eu-approved-avastin","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Hypertension"},{"rate":"15–25%","effect":"Proteinuria"},{"rate":"15–20%","effect":"Hemorrhage (all grades)"},{"rate":"10–15%","effect":"Thromboembolism"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–20%","effect":"Fatigue"},{"rate":"10–15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt cancer progression.","oneSentence":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:47.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Glioblastoma"},{"name":"Metastatic renal cell carcinoma"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT04238663","phase":"PHASE1","title":"Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-09-24","conditions":"Healthy Volunteers","enrollment":115},{"nctId":"NCT03296163","phase":"PHASE3","title":"A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2018-02-06","conditions":"Non-small Cell Lung Cancer","enrollment":627},{"nctId":"NCT03293654","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2017-12-07","conditions":"Healthy Volunteers","enrollment":114},{"nctId":"NCT04238650","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-08-02","conditions":"Healthy Volunteers, Male, Japanese","enrollment":49},{"nctId":"NCT03131700","phase":"PHASE1","title":"Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator","status":"WITHDRAWN","sponsor":"TRPHARM","startDate":"2017-12","conditions":"Healthy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bevacizumab","bevacizumab"],"phase":"phase_3","status":"active","brandName":"EU-approved Avastin®","genericName":"EU-approved Avastin®","companyName":"mAbxience Research S.L.","companyId":"mabxience-research-s-l","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}